+15.1%
ABNB vs GSK
+48.7%
-33.6%
-37.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.8% | +0.2% | -3.0% | -2.8% |
| 7D | -7.4% | -3.6% | -3.8% | -7.2% |
| 30D | -8.2% | -5.9% | -2.2% | -7.8% |
| 3M | +29.1% | -4.3% | +33.4% | +29.6% |
| 6M | +26.6% | -10.8% | +37.4% | +27.4% |
| YTD | +25.0% | +1.8% | +23.2% | +25.1% |
| 1Y | +37.0% | +23.5% | +13.5% | +36.0% |
| All | +15.1% | +48.7% | -33.6% | +5.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling